FMP
F-star Therapeutics, Inc.
FSTX
NASDAQ
Inactive Equity
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
7.12 USD
0 (0%)
Latest FSTX News
Seeking Alpha
Jan 28, 2023
F-star's Delayed Acquisition Presents A Risky Opportunity
FSTX seems undervalued, even at the $7.12 takeover bid. The CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns.
Seeking Alpha
Jul 29, 2022
F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
F-star Therapeutics announced in June that they would be acquired by InvoX, causing shares to soar. InvoX is pricing their bid at $7.12 a share; the offer is set to close on the third of August.
Zacks Investment Research
Jul 15, 2022
New Strong Buy Stocks for July 15th
GIL, PBR, CVLG, FSTX and CVBF have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2022.
Zacks Investment Research
Jun 24, 2022
F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.
Benzinga
Jun 23, 2022
F-star Therapeutics Shares Are Rallying Today - Read Why
invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical Limited, has agreed to acquire F-star Therapeutics Inc (NASDAQ: FSTX) for $7.12 per share. The proposed acquisition values F-star at approximately $161 million.
Zacks Investment Research
May 10, 2022
Fstar Therapeutics, Inc. (FSTX) Reports Q1 Loss, Tops Revenue Estimates
Fstar Therapeutics, Inc. (FSTX) delivered earnings and revenue surprises of 9.52% and 10.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research
May 3, 2022
Fstar Therapeutics, Inc. (FSTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Fstar Therapeutics, Inc. (FSTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seeking Alpha
Mar 14, 2022
F-Star Therapeutics, Inc. (FSTX) CEO Eliot Forster On Q4 2021 Results - Earnings Call Transcript
F-Star Therapeutics, Inc. (FSTX) CEO Eliot Forster On Q4 2021 Results - Earnings Call Transcript
GlobeNewsWire
Mar 10, 2022
F-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare Conference
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that management will be presenting a corporate overview and be available for 1-on-1 meetings at the 32nd Annual Oppenheimer Healthcare Conference taking place virtually on March 15-17, 2022.
GlobeNewsWire
Mar 2, 2022
F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that the Company will hold a conference call and webcast on March 14, 2022, at 9:00 a.m. EST to review fourth quarter and full-year 2021 financial results and provide a corporate update.
